(Q50069007)

24 February 2018

title

Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models. (English)

1 reference

24 February 2018

0 references

1

1 reference

24 February 2018

Shitij Kapur

5

1 reference

24 February 2018

author name string

Greg E Reckless

2

1 reference

24 February 2018

Karen B L Barlow

3

1 reference

24 February 2018

José N Nobrega

4

1 reference

24 February 2018

publication date

19 November 2010

1 reference

24 February 2018

The International Journal of Neuropsychopharmacology

published in

1 reference

24 February 2018

volume

14

1 reference

24 February 2018

issue

9

1 reference

24 February 2018

page(s)

1165-1178

1 reference

24 February 2018

Do we still believe in the dopamine hypothesis? New data bring new evidence

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Pharmacologic properties of (-)-3PPP (preclamol) in man

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Phase 1 study of a new antipsychotic drug, OPC-4392

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Induction of c-fos mRNA Expression in Rat Striatum by Neuroleptic Drugs

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Supersensitivity to apomorphine following destruction of the ascending dopamine neurons: Quantification using the rotational model

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

D2 dopamine receptor antagonists induce fos and related proteins in rat striatal neurons

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Teaching old receptors new tricks: biasing seven-transmembrane receptors

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Partial agonism and schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Studies on 2(1H)-quinolinone derivatives as neuroleptic agents I. Synthesis and biological activities of (4-phenyl-1-piperazinyl)-propoxy-2(1H)-quinolinone derivatives.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Emerging drugs for schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Dopamine partial agonists: a new class of antipsychotic

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Psychotomimetic opiate receptors labeled and visualized with (+)-[3H]3-(3-hydroxyphenyl)-N-(1-propyl)piperidine

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Partial dopamine agonists in the treatment of psychosis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Pharmacokinetics and endocrine effects of terguride in healthy subjects

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Terguride, a mixed dopamine agonist-antagonist, in animal models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Testing the validity of c-fos expression profiling to aid the therapeutic classification of psychoactive drugs.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Recruitment of beta-arrestin2 to the dopamine D2 receptor: insights into anti-psychotic and anti-parkinsonian drug receptor signaling.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Effect of 7-(3-[4-(2,3-dimethylphenyl)piperazinyl]propoxy)- 2(1H)-quinolinone (OPC-4392), a newly synthesized agonist for presynaptic dopamine D2 receptor, on tyrosine hydroxylation in rat striatal slices

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Antipsychotic drug action: antagonism, inverse agonism or partial agonism

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Mechanisms underlying agonist efficacy

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

The regulation and function of c-fos and other immediate early genes in the nervous system

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Half a century of antipsychotics and still a central role for dopamine D2 receptors

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

The dopamine hypothesis of schizophrenia: version III--the final common pathway

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D(2)-receptor and serotonin 5-HT(1A)-receptor affinities

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

https://api.crossref.org/works/10.1017%2FS1461145710001343

1 reference

7 January 2021

Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001343

7 January 2021

10.1017/S1461145710001343

Identifiers

DOI

1 reference

24 February 2018

1 reference

24 February 2018